NRG-GY006 (2025; 448 eligible): Adding triapine to cisplatin chemoradiation for locally advanced cervical/vaginal cancer did not improve OS (HR 1.018, 95% CI 0.634-1.635) or PFS (HR 1.021). Median follow-up 28 months. No proven benefit. #GynOnc#CervicalCancer#ClinicalTrials
Constipation while taking cancer pain medicines? Opioids can slow your bowels. Drink fluids if allowed, keep a stool record and ask your cancer team about a laxative plan. Severe belly pain, vomiting or swelling? Seek urgent care. #CancerCare#PainManagement#WomensHealth
After cancer surgery with an ileostomy (bowel stoma)? Keep the surrounding skin clean and dry; note unusually watery or high output. A dark/purple stoma, repeated vomiting, dizziness or little urine needs urgent medical advice. #CancerCare#OstomyCare#WomensHealth
GOG281/LOGS: Recurrent low-grade serous ovarian cancer (n=260): trametinib improved PFS vs standard care (13.0 vs 7.2 mo; HR 0.48; 2022). 2026 exploratory study (n=170) linked high pERK to greater PFS benefit—not a validated selection test. #GynOnc#OvarianCancer#ClinicalTrials
OVHIPEC-1 (NEJM 2018; Lancet Oncol 2023; n=245): In stage III ovarian cancer after NACT, cisplatin HIPEC at interval surgery improved median PFS (14.3 vs 10.7 mo; HR 0.63) and OS (44.9 vs 33.3 mo; HR 0.70). Selected patients only. #GynOnc#OvarianCancer#HIPEC
Tingling, numbness or burning in your hands or feet during chemotherapy? Tell your cancer team early—it may be nerve damage. Wear non-slip footwear, check water temperature and protect against falls. Don't stop treatment yourself. #CancerCare#Chemotherapy#WomensHealth
DESKTOP III (NEJM 2021; n=407): At first platinum-sensitive ovarian cancer relapse, AGO-selected patients had longer median OS with surgery + chemo vs chemo alone (53.7 vs 46.0 mo; HR 0.75). CC0 among operated: 75.5%. Selection is key. #GynOnc#OvarianCancer#ClinicalTrials
Hot flashes or night sweats after ovary removal or pelvic cancer treatment? Keep your room cool, wear light layers and note triggers. Relief is possible—ask your cancer team about safe options before taking hormones or supplements. #WomensHealth#CancerCare#Menopause
INTERLACE (Lancet 2024; phase III, n=500): 6 weeks of weekly carboplatin/paclitaxel before chemoradiation improved 5-year OS (80% vs 72%; HR 0.60) and PFS (72% vs 64%; HR 0.65) in locally advanced cervical cancer. Grade ≥3 AEs: 59% vs 48%. #GynOnc#CervicalCancer#ClinicalTrials
Cancer treatment can increase blood-clot risk. New swelling, pain or warmth in ONE leg? Contact your cancer team promptly. Sudden breathlessness, chest pain or coughing blood? Seek emergency care NOW. #CancerCare#BloodClots#WomensHealth
PORTEC-4a (2026; n=564): Molecular-guided adjuvant care for high-intermediate-risk endometrial cancer met noninferiority vs vaginal brachytherapy for 5-year vaginal recurrence (4.5% vs 1.6%; p=0.005), despite numerically higher rates. #GynOnc#EndometrialCancer#ClinicalTrials
Bleeding after sex is NOT something to ignore. It often has non-cancer causes, but can be a sign of cervical disease. If it happens, book a gynaecology check-up; don't self-treat or wait for it to recur. #CervicalCancer#WomensHealth#CancerAwareness
KEYNOTE-826 5-year follow-up (JAMA Oncol 2026; n=617): In persistent/recurrent/metastatic cervical cancer, pembrolizumab + chemo ± bevacizumab maintained OS benefit vs placebo + chemo: ITT median 26.4 vs 16.8 mo (HR 0.64). Exploratory. #GynOnc#CervicalCancer#ClinicalTrials
Mouth sores during chemotherapy? Use a soft toothbrush, sip water, try bland soft foods, and avoid alcohol-based mouthwash or spicy foods. Tell your cancer team early—especially if pain stops you eating or drinking. #CancerCare#Chemotherapy#WomensHealth
SHAPE (NEJM 2024; n=700): In selected low-risk IA2–IB1 cervical cancer (≤2 cm), simple vs radical hysterectomy had 3-year pelvic recurrence of 2.52% vs 2.17% (noninferior), with less urinary dysfunction. Nodal assessment is essential. #GynOnc#CervicalCancer#ClinicalTrials
RACC (n=900): robotic vs open radical hysterectomy reduced intraoperative complications (5.7% vs 10%), blood loss (75 vs 250 mL) and stay (3 vs 5 days), but not 30-day complications (33.4% vs 34.8%). Oncologic noninferiority remains unproven. #CervicalCancer#GynOnc
RUBY (2024 OS update; phase III, n=494): In primary advanced/first recurrent endometrial cancer, dostarlimab + carboplatin/paclitaxel then maintenance improved OS vs chemo alone (HR 0.69); dMMR/MSI-H subgroup HR 0.32. #GynOnc#EndometrialCancer#ClinicalTrials